Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2016

Bohrer LR, Chaffee TS, Chuntova P, Brady NJ, Witschen PM, Kemp SE, et al. ADAM17 in tumor associated leukocytes regulates inflammatory mediators and promotes mammary tumor formation. Genes Cancer. 2016;7(7-8):240-253.

Carroll VA, Lafferty MK, Marchionni L, Bryant JL, Gallo RC, Garzino-Demo A. Expression of HIV-1 matrix protein p17 and association with B-cell lymphoma in HIV-1 transgenic mice. Proc Natl Acad Sci U S A. 2016;113(46):13168-13173.

Graves HK, Wang P, Lagarde M, Chen Z, Tyler JK. Mutations that prevent or mimic persistent post-translational modifications of the histone H3 globular domain cause lethality and growth defects in Drosophila. Epigenetics Chromatin. 2016;9:9.

Ouseph MM, Simons M, Treaba DO, Yakirevich E, Green PH, Bhagat G, et al. Fatal Sepsis in a Patient With Celiac Disease-Associated Hyposplenism. ACG Case Rep J. 2016;3(4):e140.

Magro CM, Nguyen GH. Keratoderma-like T cell dyscrasia: A report of 13 cases and its distinction from mycosis fungoides palmaris et plantaris. Indian J Dermatol Venereol Leprol. 2016;82(4):395-403.

Isella C, Terrasi A, Bellomo SE, Petti C, Galatola G, Muratore A, et al. Corrigendum: Stromal contribution to the colorectal cancer transcriptome. Nat Genet. 2016;48(10):1296.

Patel AD, Schneider Y, Saumoy M, Maltz C, Yeo H, Jessurun J, et al. Idiopathic Myointimal Hyperplasia of the Mesenteric Veins. ACG Case Rep J. 2016;3(4):e84.

Riveiro ME, Astorgues-Xerri L, Vazquez R, Frapolli R, Kwee I, Rinaldi A, et al. OTX015 (MK-8628), a novel BET inhibitor, exhibits antitumor activity in non-small cell and small cell lung cancer models harboring different oncogenic mutations. Oncotarget. 2016;7(51):84675-84687.

Graff RE, Pettersson A, Lis RT, Ahearn TU, Markt SC, Wilson KM, et al. Dietary lycopene intake and risk of prostate cancer defined by ERG protein expression. Am J Clin Nutr. 2016;103(3):851-60.

Thakkar A, Wang B, Picon-Ruiz M, Buchwald P, Ince TA. Vitamin D and androgen receptor-targeted therapy for triple-negative breast cancer. Breast Cancer Res Treat. 2016;157(1):77-90.